Table 1. Baseline Demographics and Clinical Characteristics of Study Participants.

	Placebo (n=194)	Vortioxetine (n=198)	Duloxetine (n=210)
Age (years)
Mean (SD)	45.0 (12.1)	44.2 (12.2)	45.7 (11.5)
Range	18–64	18–65	20–65
Gender, n (%)
Male	75 (38.7%)	63 (31.8%)	72 (34.3%)
Female	119 (61.3%)	135 (68.2%)	138 (65.7%)
Race, n (%)
Caucasian	171 (88.1%)	169 (85.4%)	176 (83.8%)
Black	20 (10.3%)	28 (14.1%)	27 (12.9%)
Asian	1 (0.5%)	1 (0.5%)	6 (2.9%)
Other	2 (1.0%)	0	1 (0.5%)
DSST, mean (SD)
Number of correct symbols	43.5 (12.1)	42.3 (11.7)	43.4 (12.1)
CPFQ, mean (SD)
Total score	30.2 (4.5)	29.5 (5.3)	29.3 (4.9)
PDQ, mean (SD)
Total score	43.9 (10.6)	43.5 (10.9)	41.2 (12.6)
MADRS, mean (SD)
Total score	31.9 (3.8)	31.4 (3.9)	31.7 (3.8)
CGI-S, mean (SD)
Score	4.6 (0.6)	4.6 (0.6)	4.6 (0.6)